# Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors

> **NCT00301756** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 32 (actual)

## Conditions studied

- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma
- Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor
- Recurrent Ovarian Carcinoma
- Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor
- Stage III Ovarian Cancer
- Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor
- Stage IV Ovarian Cancer

## Interventions

- **DRUG:** Belinostat
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00301756
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2009-08
- **Final completion:** 2012-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301756, "Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00301756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*